WA manufacturer’s stunning 377 per cent share price rise

Shares in nerve growth therapy developer Orthocell (ASX: OCC) have surged 377 per cent on positive news from clinical trials of its CelGro tissue repair device. The company, which developed and manufactures CelGro at its internationally-approved facility in Perth, passed a critical trial with patients with damaged nerves. The first four patients to receive surgery…

Details